These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 33686136)

  • 1. Author Correction: Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index.
    Lee J; Cha C; Ahn SG; Kim D; Park S; Bae SJ; Kim J; Park HS; Park S; Kim SI; Park BW; Jeong J
    Sci Rep; 2021 Mar; 11(1):5415. PubMed ID: 33686136
    [No Abstract]   [Full Text] [Related]  

  • 2. Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index.
    Lee J; Cha C; Ahn SG; Kim D; Park S; Bae SJ; Kim J; Park HS; Park S; Kim SI; Park BW; Jeong J
    Sci Rep; 2020 Oct; 10(1):16850. PubMed ID: 33033359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence.
    Conforti F; Pala L; Pagan E; Viale G; Bagnardi V; Peruzzotti G; De Pas T; Bianco N; Graffeo R; Rocco EG; Vingiani A; Gelber RD; Coates AS; Colleoni M; Goldhirsch A
    Breast Cancer Res; 2019 Dec; 21(1):153. PubMed ID: 31888717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of the free web-based image analysis application ImmunoRatio for assessment of Ki-67 labelling index in breast cancer.
    Yeo MK; Kim HE; Kim SH; Chae BJ; Song BJ; Lee A
    J Clin Pathol; 2017 Aug; 70(8):715-719. PubMed ID: 28298390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer.
    Hao S; He ZX; Yu KD; Yang WT; Shao ZM
    Oncotarget; 2016 Apr; 7(17):24824-31. PubMed ID: 27050075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated characterization and counting of Ki-67 protein for breast cancer prognosis: A quantitative immunohistochemistry approach.
    Mungle T; Tewary S; Arun I; Basak B; Agarwal S; Ahmed R; Chatterjee S; Maity AK; Chakraborty C
    Comput Methods Programs Biomed; 2017 Feb; 139():149-161. PubMed ID: 28187885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labelling index in women with primary breast cancer.
    Dardes RD; Horiguchi J; Jordan VC
    Int J Oncol; 2000 Jan; 16(1):25-30. PubMed ID: 10601544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.
    Noske A; Anders SI; Ettl J; Hapfelmeier A; Steiger K; Specht K; Weichert W; Kiechle M; Klein E
    Breast; 2020 Feb; 49():101-107. PubMed ID: 31786414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer.
    Khan QJ; Kimler BF; O'Dea AP; Zalles CM; Sharma P; Fabian CJ
    Breast Cancer Res; 2007; 9(3):R35. PubMed ID: 17537236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The proliferative activity in epithelial hyperplasia of the breast].
    Kaneko M; Arihiro K; Fujii S; Inai K
    Gan To Kagaku Ryoho; 1995 Apr; 22 Suppl 1():46-51. PubMed ID: 7747992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences.
    Gaglia P; Bernardi A; Venesio T; Caldarola B; Lauro D; Cappa AP; Calderini P; Liscia DS
    Eur J Cancer; 1993; 29A(11):1509-13. PubMed ID: 8217353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.
    DeCensi A; Guerrieri-Gonzaga A; Gandini S; Serrano D; Cazzaniga M; Mora S; Johansson H; Lien EA; Pruneri G; Viale G; Bonanni B
    Ann Oncol; 2011 Mar; 22(3):582-587. PubMed ID: 20716629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis.
    Rinnerthaler G; Gampenrieder SP; Greil R
    Memo; 2018; 11(3):208-212. PubMed ID: 30220928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleolar organizer region score and Ki-67 labelling index in high-grade gliomas and metastatic brain tumours.
    Hara A; Hirayama H; Sakai N; Yamada H; Tanaka T; Mori H
    Acta Neurochir (Wien); 1991; 109(1-2):37-41. PubMed ID: 1648862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors for Premenopausal Breast Cancer in Bangladesh.
    Iqbal J; Ferdousy T; Dipi R; Salim R; Wu W; Narod SA; Kotsopoulos J; Mostafa MG; Ginsburg O
    Int J Breast Cancer; 2015; 2015():612042. PubMed ID: 26229688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Ki-67 as a potential biomarker in patients with breast cancer.
    Ragab HM; Samy N; Afify M; El Maksoud NA; Shaaban HM
    J Genet Eng Biotechnol; 2018 Dec; 16(2):479-484. PubMed ID: 30733763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early adult body weight, body mass index, and premenopausal bilateral breast cancer: data from a case-control study.
    Ursin G; Paganini-Hill A; Siemiatycki J; Thompson WD; Haile RW
    Breast Cancer Res Treat; 1995; 33(1):75-82. PubMed ID: 7749135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index had different effects on premenopausal and postmenopausal breast cancer risks: a dose-response meta-analysis with 3,318,796 subjects from 31 cohort studies.
    Chen Y; Liu L; Zhou Q; Imam MU; Cai J; Wang Y; Qi M; Sun P; Ping Z; Fu X
    BMC Public Health; 2017 Dec; 17(1):936. PubMed ID: 29216920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.